Clinical Trial Update: Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating a cancer lysate vaccine with Montanide ISA-51 VG, entinostat, and nivolumab as adjuvant therapy after chemoradiation (± surgery) for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Cancer lysate vaccine
• Entinostat (entinostat)
• Montanide ISA-51 VG (Montanide ISA-51 VG)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms, Esophageal Neoplasms | Phase 1, Phase 2 | Status: WITHDRAWN